Compounder Can't Duck Drug Marketing Suit, Allergan Says
Allergan has asked a California federal judge not to toss its suit alleging Imprimis Pharmaceuticals illegally manufactures and sells unapproved new drugs under a drug compounding loophole in FDA regulations, saying...To view the full article, register now.
Already a subscriber? Click here to view full article